HONG KONG, May 27, 2026 (GLOBE NEWSWIRE) — Futu Holdings Limited (“Futu” or the “Company”) (Nasdaq: Futu), today announced that as of this announcement, the cumulative repurchases under its share repurchase program have reached approximately US$290 million worth of its American depositary shares (“ADSs”), representing its Class A ordinary shares. The repurchases were conducted under the Company’s share repurchase program previously announced on November 18, 2025, under which the Company may repurchase up to US$800 million worth of ADSs for a period ending December 31, 2027. Subject to market conditions, the Company may continue to execute repurchases from time to time under the existing share repurchase program. About Futu Holdings Limited Futu Holdings Limited (Nasdaq: FUTU) is an advanced technology...

TAIPEI, Taiwan, May 26, 2026 (GLOBE NEWSWIRE) — Astera Labs, Inc. (Nasdaq: ALAB), a leader in semiconductor-based connectivity solutions for rack-scale AI infrastructure, will host press and industry analysts at Computex 2026 in the company’s room at the Taipei Nangang Exhibition Center, Hall 1 (TaiNEX 1), Room 303, third floor. WHAT: Astera Labs will use its Computex program to highlight the company’s latest news, rack-scale AI connectivity strategy, and collaboration with leading AI platform providers and Taiwan system and manufacturing partners. Attendees will get a look at Astera Labs’ complete connectivity portfolio, including the first public demonstration of the Scorpio™ X-Series 320 Lane Smart Fabric Switch, ultra-low latency linear optical connectivity, COSMOS-enabled rack-level validation, and production-ready...

SHANGHAI, May 26, 2026 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that a randomized, double-blind, placebo-controlled, multi-center phase III clinical study (“NEOTORCH”, NCT04158440) of the company’s product toripalimab in combination with platinum-containing doublet chemotherapy as perioperative treatment for resectable stage II-III non-small cell lung cancer (“NSCLC”) patients has finished its final analysis. The primary endpoints of event-free survival (“EFS”) and major pathological response (“MPR”) rate in the stage II-III population, as well as the MPR rate in the stage III population, met the pre-defined efficacy boundary....

HighlightsSQM reported total revenues for the three months ended March 31, 2026 of US$1,760.1 million compared to total revenues of US$1,036.6 million for the same period last year.Net income for the three months ended March 31, 2026 of US$364.7 million or US$1.28 per share, compared to US$137.5 million or US$0.48 per share for the same period last year.In lithium: Strong sales volumes amidst strong market demand. Moving-up sales volumes guidance for the year.In SPN: Stronger than expected quarter in both volumes and prices. Moving-up sales volumes for the year. SQM will hold a conference call to discuss these results on Wednesday, May 27, 2026 at 12:00pm EDT (12:00pm Chile time).Participant Call link: https://register-conf.media-server.com/register/BIf194b8fef0d7479a82018f16e2c31fe3Webcast: https://edge.media-server.com/mmc/p/9qtcu4gcSANTIAGO,...

LA JOLLA, Calif., May 26, 2026 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the completion of last patient last visit (LPLV) in its Phase 2 clinical trial, MN-001-NATG-202, evaluating MN-001 (tipelukast) for the treatment of hypertriglyceridemia and nonalcoholic fatty liver disease (NAFLD) associated with type 2 diabetes mellitus (T2DM). The MN-001-NATG-202 study is a multicenter, randomized, double-blind, placebo-controlled trial evaluating MN-001 (tipelukast). Patients were randomized 1:1 to receive either 500 mg/day of MN-001 (tipelukast) or placebo for 24 weeks.　The co-primary endpoints are (1) change from baseline in liver fat content, as measured by controlled attenuation...

NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) — Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, Prader-Willi Syndrome, depression, and other central nervous system (CNS) disorders, today announced that the Company will present at the Jefferies Global Healthcare Conference as follows:DATE: Wednesday, June 3, 2026TIME: 4:20PM EDTWEBCAST: Click Here   The live and archived webcast will be accessible from the Company’s website at https://investors.brightmindsbio.com/news-events/presentations under Events and Presentation. The replay of the webcast will be accessible for 30 days. Bright Minds further releases that the Company has granted stock options (the “Options”)...